Why RDW, TE, OTLK Stocks Posted Double-Digit Gains On Tuesday

• RDW stock closed up 26%, gaining from the space sector euphoria sparked by SpaceX’s highly-anticipated market debut. 
• TE jumped more than 29% after a filing revealed that a major shareholder received an additional 4.27 million common shares of the company.
• OTLK also soared 29% after securing a major regulatory win from the FDA tied to its eye disease drug Lytenava.

Redwire Corp. (RDW), T1 Energy Inc. (TE), and Outlook Therapeutics Inc. (OTLK) shares soared, clocking double-digit gains to emerge as some of the top gainers on Tuesday.

RDW stock closed up 26%, gaining from the space sector euphoria sparked by SpaceX’s highly anticipated market debut. TE jumped more than 29%, extending its rally due to optimism from significant institutional backing, while OTLK also soared 29% on confidence around its eye disease therapy.

Redwire On Track For Best Monthly Gains

The Jacksonville, Florida-based company has ridden a broader rally in space-related stocks following last week’s SpaceX S-1 prospectus filing, which sparked gains across companies tied to space exploration, launch systems, satellites, lunar missions, and supporting infrastructure.

Tuesday’s sharp advance has now put RDW on track for its best month ever, with the stock soaring nearly 140% in May.

Redwire has also gained momentum on the back of a series of lunar robotics and defense-related developments. Last week, the company announced the successful testing and delivery of its MANUS robotic lunar arm prototype for the European Space Agency’s Argonaut lunar lander program, designed to help transport and manage cargo on the Moon.

The aerospace company has also secured multiple defense contracts, including a $15 million follow-on order from the United States Army for its Stalker unmanned aerial systems and a separate multi-year, high eight-figure deal from a NATO ally for its Penguin Mk3 drone platform.

Retail sentiment around the stock has stayed in the ‘extremely bullish’ territory over the last three months on Stocktwits, with message volumes rising 552.6% in the same time.

T1 Energy Soars On Institutional Backing

Shares of T1 Energy soared on Tuesday after the company reported that its major shareholder Trina Solar (SCHWEIZ) AG received an additional 4.27 million common shares of the company on Jan. 21, 2026 as part of an anti-dilution rights in a Transaction Agreement dated Nov. 6, 2024.

The Form 4 filing with the U.S. Securities and Exchange Commission showed that the shares were issued at a price of $1.70, and increased Trina Solar’s holdings to more than 53 million shares.

The company’s shares have been climbing in recent months amid strong institutional backing, bullish analyst commentary, and solid earnings, with Tuesday’s surge putting the company on track for its best performance since October last year.

Earlier this month, hedge fund Situational Awareness LP, run by former OpenAI researcher Leopold Aschenbrenner, disclosed a $44 million stake in T1 Energy, further boosting sentiment.

TE stock has soared a whopping 816% in the last 12 months. Retail sentiment around the stock has stayed in the ‘extremely bullish’ territory, with ‘extremely high’ message volumes over the past month.

Outlook Therapeutics Rallies On FDA Victory

The biopharma company recorded its best day in over two years after securing a major regulatory win from the U.S. Food and Drug Administration (FDA) tied to its eye disease drug Lytenava.

The company said that the agency had granted its appeal through the Formal Dispute Resolution process, concluding that sufficient evidence had been provided to support the treatment’s effectiveness in patients with neovascular age-related macular degeneration, or wet AMD.

Following the decision, the company said it plans to resubmit its Biologics License Application for Lytenava in June 2026 and expects the filing to receive a Class 1 review, potentially leading to a regulatory decision within 60 days. If approved, Lytenava could become the first FDA-approved ophthalmic formulation of Bevacizumab for retinal diseases in the U.S. The treatment has already been approved in the European Union and the United Kingdom for wet AMD.

OTLK shares have declined nearly 40% so far this year. Retail sentiment on Stocktwits has stayed in the ‘extremely bullish’ territory amid ‘extremely high’ message volumes over the past week.

For updates and corrections, email newsroom[at]stocktwits[dot]com.